In patients with melanoma under anti-PD-1 therapy, we observed a decrease in the percentage of CD57+ Vδ1 T cells, an increase in TRDV1 repertoire diversity, but no skewing of the CDR3 spectratype, suggesting polyclonal expansions of less-abundant CD57− Vδ1 clones. This evidence concerns the gene TRDV1 and melanoma.